X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement aims to advance the innovative bispecific antibody drug project by leveraging Sanyou's world-leading core technology platform for integrated R&D and preclinical development and Sinorda's rich experience in preclinical and clinical oncology immunotherapy.
Lead Product(s): Bispecific Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sinorda Biomedicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 22, 2023
Details:
Under the agreement, the companies will develop therapeutic biological products in the therapeutic area of oncology through Sanyou's world-leading core technology platform.
Lead Product(s): Biological Product
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Hangzhou Zhongmei Huadong Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 28, 2023
Details:
Sanyou will provide preclinical R&D services including drug screening, pharmacology research, process development and quality control of various biological drugs including monoclonal antibodies, multi-specific antibodies, ADC drugs, etc.
Lead Product(s): Antibody
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Dragon Sail Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 20, 2022
Details:
Preclinical study data of BC008 antibody injection showed drug can specifically target and bind CLDN18.2 molecules on cell surface, and play an anti-tumor role by specifically killing CLDN18.2-positive tumor cells through Fc-mediated immune effector functions.
Lead Product(s): BC008
Therapeutic Area: Oncology Product Name: BC008
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: Dragon Boat Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2022
Details:
Agreement aims to develop fully human antibody drug for covid-19 for monotherapy or combination treatment of covid-19.
Lead Product(s): Antibody drug conjugate
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Shanghai Henlius Biotech
Deal Size: $3.5 million Upfront Cash: Undisclosed
Deal Type: Agreement May 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
